医药生物行业：IBD治疗领域存在未满足的需求，关注新靶点、新机制－创新药盘点系列报告

医药生物行业：2025ASCO大会国内重点研究总结报告

中国诸多创新药资产近年来逐步进入全球视野，临床数据在各类学术会议上占据越发重要的地位，BD授权金额及数 量持续攀升，全球影响力持续扩大。伴随着临床数据的驱动以及持续强化的BD预期的催化，创新药板块在25H1迎来一轮估值的修复，越来越多中国资产的全球价值开始获得认同。信达生物核心肿瘤管线资产IBI363（PD1/IL2α）在实体瘤上有望实现“热” 肿瘤超越+“冷”肿瘤突破，具备超重磅炸弹潜力。康方生物作为全球双抗引领者，其核心产品依沃西（AK112，PD-1/VEGF双 抗）成为全球首个在1L肺癌治疗中mPFS超越K药的双抗，具有成为新一代IO基石药物的巨大潜力。

Global Adeno-Associated Virus (AAV) CDMO Market Size and Share Analysis - Growth, Trends and Forecas...

Global Airport Lounges Market Size - Industry Report On Share, Growth Trends and Forecasts Analysis

Global Aluminum Electrolytic Capacitors Market Size and Share Analysis - Growth Trends and Forecasts

Global Artillery Ammunition Casing Market Size and Share Analysis - Growth Trends and Forecasts

Anti-plagiarism software enables end-users to compare written content with that available on the Internet to check whether such content is original or has been plagiarized from another person/organization/domain.

The market by value in this report is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography. • Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The Group values input and feedback of its stakeholders as they are closely connected to the Group’s development. Internal and external stakeholders have been involved in regular engagement activities to share their views regarding the Group’s operations and performances, which are as shown below.